Response to: Cholangiocarcinoma patients with FGFR2 fusions/rearrangements but primary refractory to pemigatinib: the real challenge?

Affiliations

• ¹ Hannover Medical School, Hannover, Germany; Toronto General Hospital, Toronto, Canada; Princess Margaret Cancer Centre, Toronto, Canada. Electronic address: vogela@me.com.
• ² Incyte Corporation, Wilmington, USA.
• ³ Incyte International Biosciences Sàrl, Morges, Switzerland.
• ⁴ Memorial Sloan Kettering Cancer Center, New York, USA; Weill Medical College at Cornell University, New York, USA; Trinity College Dublin School of Medicine, Dublin, Ireland.